The plan for exovex.
Enquirer AI is the outbound engine of Enquirer Consulting Group.
You asked for questions and a proposal. Here are both, in order.
Your answers, then the plan
The five questions from Paul's email, answered out loud. Then how the engine would actually run for Exocel Bio: the three lanes, LinkedIn switched back on, Salesforce, the AI brain, the four months.
The scope, the terms, the number
Dan Reeves founded Enquirer Consulting Group and engineers the engine. About 30 minutes, live, built from what you tell us today. If someone else is part of the decision, bring them.
A yes or a no
Both are fine. A yes starts week one of the pilot. A no saves everyone the time. What we will not do is send a number cold and leave you to guess at it.
20,000 in the database. 2,000 have bought. 500 keep buying.
Three customers. Three conversations. One engine.
Bought, then stopped
"Another rep in person did a better job."
Around 1,500 practices that have already bought exovex and stopped. They know the product and the price. They left over economics or a rep. A win-back, one to one, by name, with a reason to reorder now. Fastest lane, so it goes first.
On a competitor's exosome
"Usually that's a price and potency discussion."
They buy exosomes, just not yours. The conversation is the case you already make, in your words: potency and price per billion. Plus your standing offers, the microscope, the lab tour, a call with your Chief Science Officer.
Not using exosomes yet
"You have to educate them. It's a longer sales cycle."
Med spas running microneedling and PRP, practices with the energy devices. Paced as a longer nurture, with your position on samples stated up front rather than discovered later.
Up to three accounts, working every day, inside your lines.
The accounts
Real LinkedIn accounts, in real names. Yours if you want it there, a team member's, or accounts we provide and run on Exocel Bio's behalf. Each set up first, so a practice owner who clicks through sees exovex properly.
The right person, by name
The owner, the medical director, the dermatologist, the plastic surgeon, the trichologist at each practice in each lane. Name, role and practice checked before anyone is contacted. No front desk in between.
Written for one person
A connection note and a short follow-up series, each written for that person from their profile and their practice, from wording you approved. No two people get the same message.
Paced deliberately
Well inside LinkedIn's weekly limits, in the practice's own time zone. The first two weeks run slower on purpose. A no stops the sequence and that person is left alone, on both channels.
One-to-one email to the same decision makers. Never from exocelbio.com.
Separate sending domains, set up and warmed by us, so your own domain is never exposed to outbound.
Every address verified before it is used. Authentication and inbox placement tested before the first message goes out.
Your name, your sign-off, your business address and a one-click opt-out on every message, honored immediately. The same person reading the replies.
The same routing: a reply lands in Salesforce and with the right rep, whichever channel it came from.
Every reply lands in Salesforce and with the right rep the same day.
Today
- A reply lands in an inbox or the site form, and someone re-keys it.
- There is no rule that says which rep gets it, or by when.
- The 1,500 who stopped get a promotion, not a win-back built on why each one left.
- Nobody can see, lane by lane, what the market is answering.
With the engine
- The reply is logged against the practice with the whole thread. The stage moves.
- The rep who owns that account gets it the same day, with the full context, by whatever territory rule you give us.
- Lapsed accounts due a touch are flagged. A no is marked and left alone.
- A dashboard from day one: reached, replied, conversation, meeting, per lane.
It does the admin. Your people do the selling.
The morning brief
Who replied overnight in each lane. Which rep owes a follow-up. Which lapsed accounts are due a touch. What is stuck and why.
Follow-ups drafted
In your approved language, with your compliance lines written in as rules. Nothing sends without a person saying yes.
Salesforce kept current
Logs the reply, moves the stage, assigns the rep. Nothing changes in Salesforce that a person has not seen, and your admin can switch it off in a click.
Yours
It runs in your environment, on your own accounts and subscriptions. No dependency on us after handover. We install it with your team on a working session and train the person who runs it.
You approve every line before it sends.
Written to the claim set your sign-off owner approves in writing, and nothing outside it: no names, no protocols, no outcomes.
B2B only, to practices, their owners and their medical directors. Never to patients or consumers.
Your potency and price-per-billion positioning, in the exact words your sign-off owner gives us. Nothing added, nothing implied.
Your named sign-off owner approves the wording before week one, and every change after it.
A pilot first. Then the build.
Step 1: the pilot, 30 days
Up to three accounts, run by our team, into the practices you name. Week one: the buyer set, the exclusions and your sign-off on the messaging. Weeks two to four: live outreach, every reply routed to your named owner the same day, and a short weekly read on what your market is answering.
On the call we agree a conversations target for the first 30 days. If we miss it, the following month is on us.
What counts as a conversation, and what we need from you to get there, is agreed on the same call and written down.
Step 2: the build, four months
Four months, starting from what the pilot proved. The full engine across all three lanes, wired into Salesforce, the brain installed with your team, run with you, your person trained as it runs.
Then we hand you the keys. The lists, the messaging, the data, the Salesforce wiring and the brain are yours. Accounts belonging to your own people stay with them. No license you do not hold, no subscription you cannot see.
Four months, fixed. Then it is yours.
Stood up
Accounts live. The win-back lane first, then the competitor lane. Salesforce wired for replies. Sending before the month closes, with the first replies read and routed the same business day.
The whole machine
All three lanes running. Email alongside LinkedIn. The brain installed with your team. The dashboard live, lane by lane.
Your person runs it
We are alongside, not in front. Optimizing on real reply and conversation data. The playbook written as it is proven.
Handover
You own the lists, the messaging, the data, the Salesforce wiring and the brain. If you would rather we kept running it, that is an option, not the model.
The list Dan builds the proposal from.
The 20,000
A Salesforce export or access, with the named decision maker wherever you have one. Plus the third-party research you bought, if its license lets a contractor work from it. If not, we build the equivalent from our own data.
The 1,500 who stopped
With the reason where you know it: price, a rep, a bad experience. Reason codes make the first message right.
The rep map
Who is active, how territories are drawn, and how a warm lead reaches the right rep today.
The lines
What can and cannot be said about exovex in writing, and who signs it off on your side.
Exclusions
Your active accounts, anyone a rep is working right now, competitors, and anyone who has asked not to be contacted. Honored as a hard rule from day one.
The accounts and the closers
Your own LinkedIn, a team member's, or ours. And whether the microscope, the lab tour and a call with your Chief Science Officer can be offered in a first message.
Deliberately not proposed: PR, video, a website rebuild or your social. Instagram is doing its job. The gap is reaching the decision maker, so that is where this goes.
US medical companies, in their own words.
Enquirer Consulting Group provided the tools to allow us to personalize outreach at scale in a way that simply wasn't possible before.
ECG and Enquirer AI helps us identify the right people and start the conversation in a much smarter way.
The proposal call with Dan Reeves, next week.
Dan founded Enquirer Consulting Group and engineers the engine. About 30 minutes, live: the scope for Exocel Bio, the terms and the number, built from today's answers. If anyone else should be on it, tell Paul and we will work around their calendar. Paul sends the invite before this call ends.
cal.com/ecgIf you need to move it, reply to Paul Smaldone. Cell 216 386 0762.